Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Registration - Consultant

Innovative Medicines Canada / Médicaments novateurs Canada / ANDRE ALBINATI, Consultant

Registration Information

Client name: Innovative Medicines Canada / Médicaments novateurs Canada
Previous client names
Lobbyist name: ANDRE ALBINATI, Consultant
Initial registration start date: 2003-02-28
Registration status: Inactive
Registration Number: 775866-2182

Associated Communications

Total Number of Communication Reports: 41

Monthly communication reports in the last 6 months: 0

Version 2 of 25 (2004-02-09 to 2005-06-10)

Version 2 of 25 (2004-02-09 to 2005-06-10) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Registrant

Consultant lobbyist name: ANDRE ALBINATI    Lobbyist business address
Consulting firm: THE EARNSCLIFFE STRATEGY GROUP
46 ELGIN STREET
OTTAWA, ON  K1P 5K6
Canada
Position: PRINCIPAL
Telephone number: 613-563-4455  
Fax number: 613-236-9546  
 
Former public office holder: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
Payment is contingent on the success of the undertaking: No

Information about Lobbyist

Consultant lobbyist name: ANDRE ALBINATI
Business address: 300 - 46 ELGIN STREET
OTTAWA, ON  K1P 5K6
Canada
Telephone number: 613-563-4455  
Fax number: 613-563-4455  

B. Information about Client

Client: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES RX&D
1220 - 55 METCALFE STREET
OTTAWA, ON  K1P 6L5
Canada
Telephone number: 613-236-0455
Fax number: 613-236-7919  
 
Client Representative: MARC DEMARAIS
 
Parent: The client is not a subsidiary of any other parent companies.
Coalition: The client is not a coalition.
Subsidiary: The client does not have any subsidiaries that could be affected by the outcome of the undertaking.
Individual, organization or corporation: The client's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the client funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Informal communications, Meetings, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Consumer Issues, Health, Industry, Intellectual Property, Science and Technology
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program MONITORING DEVELOPMENTS & PROVIDING ADVICE RELATING TO AREAS OF POLICY INTEREST TO CANADA'S INNOVATIVE PHARMACEUTICAL INDUSTRY



Responsible Officer Name

This is the responsible officer name as provided in the most recent registration for the corporation or organization.

Name Change History:

Innovative Medicines Canada/Médicaments novateurs Canada

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name From To
Innovative Medicines Canada/Médicaments novateurs Canada 2016-01-31 2021-03-01
Canada's Research -Based Pharmaceutical Companies Rx&D 2008-08-12 2016-01-31

The following names have been used before July 2, 2008

  • Canada's Research -Based Pharmaceutical Companies Rx&D
  • CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES RX&D
  • CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES RX&D

Responsible Officer Change History

Innovative Medicines Canada / Médicaments novateurs Canada

Responsible Officer History
Responsible Officer Name From (YYYY-MM-DD) To (YYYY-MM-DD)

All Monthly Communication Reports for Innovative Medicines Canada / Médicaments novateurs Canada

ANDRE ALBINATI, Earnscliffe Strategy Group (Consultant)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-41 of 41

  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Celine Caira, Senior Policy Advisor | Office of the Minister of Innovation, Science and Industry | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2021-01-11
    Posted date: 2021-02-15
    Communication number: 2182-494329 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2020-10-15
    Posted date: 2020-11-16
    Communication number: 2182-488240 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Celine Caira, Policy Advisor | Office of the Minister of Innovation, Science and Industry | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Intellectual Property, Science and Technology, Research and Development
    Communication date: 2020-04-21
    Posted date: 2020-05-15
    Communication number: 2182-473717 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Taras Zalusky, Acting Chief of Staff | Office of the Minister of Public Services and Procurement and Accessibility | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry, International Trade, Research and Development
    Communication date: 2019-07-30
    Posted date: 2019-08-15
    Communication number: 2182-458913 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Jason Easton, Chief of Staff | Office of the Minister of Small Business and Export Promotion | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, International Trade, Research and Development
    Communication date: 2019-07-30
    Posted date: 2019-08-15
    Communication number: 2182-458912 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-06-25
    Posted date: 2019-07-15
    Communication number: 2182-456759 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Amanda Woodley, Policy Advisor | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Research and Development
    Communication date: 2019-06-03
    Posted date: 2019-07-15
    Communication number: 2182-456786 (amended from 2182-456758) View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Amanda Woodley, Policy Advisor | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Research and Development
    Communication date: 2019-06-03
    Posted date: 2019-07-15
    Communication number: 2182-454942 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Gianluca Cairo, Chief of Staff | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Research and Development
    Communication date: 2019-05-29
    Posted date: 2019-06-15
    Communication number: 2182-454183 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Jamie Innes, Director of Policy and Issues Management | Office of the Minister of International Trade | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, International Trade, Research and Development
    Communication date: 2019-05-24
    Posted date: 2019-06-15
    Communication number: 2182-454943 (amended from 2182-454181) View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Taras Zalusky, Director of Policy for Procurement and Parliamentary Affairs | Office of the Minister | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-23
    Posted date: 2019-05-15
    Communication number: 2182-451829 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Taras Zalusky, Director of Policy for Procurement and Parliamentary Affairs | Office of the Minister | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-12
    Posted date: 2019-05-15
    Communication number: 2182-451825 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Matt Stickney, Chief of Staff | Office of the Minister | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-11
    Posted date: 2019-05-15
    Communication number: 2182-451823 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Gianluca Cairo, Chief of Staff | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Science and Technology, Research and Development
    Communication date: 2019-01-18
    Posted date: 2019-02-15
    Communication number: 2182-445045 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Science and Technology, Research and Development
    Communication date: 2019-01-11
    Posted date: 2019-02-15
    Communication number: 2182-445052 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Science and Technology, Research and Development
    Communication date: 2019-01-11
    Posted date: 2019-02-15
    Communication number: 2182-443816 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Research and Development
    Communication date: 2018-11-15
    Posted date: 2018-12-15
    Communication number: 2182-440742 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-08-17
    Posted date: 2018-09-15
    Communication number: 2182-433785 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2018-06-01
    Posted date: 2018-07-16
    Communication number: 2182-431225 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Special Assistant (Policy) | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2018-04-17
    Posted date: 2018-05-15
    Communication number: 2182-426348 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Genevieve Hinse, Chief of Staff | Office of the Minister | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2018-03-28
    Posted date: 2018-04-16
    Communication number: 2182-424371 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Regional Development, Science and Technology
    Communication date: 2017-11-02
    Posted date: 2017-12-15
    Communication number: 2182-415310 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2017-09-07
    Posted date: 2017-10-16
    Communication number: 2182-409063 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Robert Asselin, Director of Policy and Budget Director | Office of the Minister | Finance Canada (FIN)

    Subject Matter of the communication: Health
    Communication date: 2017-08-17
    Posted date: 2017-09-15
    Communication number: 2182-407975 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2017-05-17
    Posted date: 2017-06-15
    Communication number: 2182-403098 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2017-04-05
    Posted date: 2017-05-15
    Communication number: 2182-400582 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2016-10-11
    Posted date: 2016-11-15
    Communication number: 2182-386738 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Robert Asselin, Director of Policy | Finance Canada (FIN)

    Subject Matter of the communication: International Trade
    Communication date: 2016-07-29
    Posted date: 2016-08-15
    Communication number: 2182-382339 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Justin To, Policy Advisor (Economic and Innovation) | Prime Minister's Office (PMO)

    Subject Matter of the communication: Intellectual Property
    Communication date: 2016-07-26
    Posted date: 2016-08-15
    Communication number: 2182-382338 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Scott Tessier, Chief of Staff | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2010-10-06
    Posted date: 2010-11-16
    Communication number: 2182-159420 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Karen Dodds, Assistant Deputy Minister | Office of the Assistant Deputy Minister | Health Canada (HC)
    • Ron Parker, Senior Assistant Deputy Minister | Industry Sector | Industry Canada

    Subject Matter of the communication: Health, Industry
    Communication date: 2010-05-31
    Posted date: 2010-06-16
    Communication number: 2182-149616 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Scott Tessier, Chief of Staff | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2010-01-06
    Posted date: 2010-02-16
    Communication number: 2182-138096 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Scott Tessier, Chief of Staff | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2009-12-22
    Posted date: 2010-01-06
    Communication number: 2182-134678 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Don Stephenson, Assistant Deputy Minister | Trade Policy and Negotiations | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Intellectual Property
    Communication date: 2009-11-10
    Posted date: 2009-12-15
    Communication number: 2182-132819 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Philip Welford, Chief of Staff | Minister's Office | Minister of State (Science & Technology)

    Subject Matter of the communication: Science and Technology
    Communication date: 2009-03-06
    Posted date: 2009-04-15
    Communication number: 2182-101134 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Benoit Violette, Senior Policy Advisor | Minister's Office | Industry Canada

    Subject Matter of the communication: Intellectual Property, Science and Technology
    Communication date: 2009-01-23
    Posted date: 2009-02-13
    Communication number: 2182-93794 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Leah Canning, Policy Advisor | Minister's Office | Health Canada (HC)
    • Laurie Throness, Senior Policy Advisor | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Intellectual Property
    Communication date: 2009-01-06
    Posted date: 2009-02-13
    Communication number: 2182-93786 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Scott Tessier, Chief of Staff | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2008-12-22
    Posted date: 2010-01-06
    Communication number: 2182-134594 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Phillip Welford, Chief of Staff | Minister's Office, Minister of State (Science & Technology) | Industry Canada

    Subject Matter of the communication: Science and Technology
    Communication date: 2008-11-20
    Posted date: 2008-12-16
    Communication number: 2182-88142 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • Kera Wilkinson, Special Assistant | Office of the Chief Government Whip | Chief Government Whip

    Subject Matter of the communication: Health
    Communication date: 2008-07-31
    Posted date: 2008-08-16
    Communication number: 2182-76835 View associated registration
  • Innovative Medicines Canada
    Consultant: ANDRE ALBINATI
    Designated Public Office Holders who participated in the communication:
    • David Pierce, Special Assistant | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2008-07-02
    Posted date: 2008-08-16
    Communication number: 2182-76834 View associated registration

Public offices held:


Date Modified: